GILEAD SCIENCES, INC. (GILD) Form 10-Q — Oct 29, 2026
Gilead's Q3 2026 revenue rose 7% to $8.3 billion, led by HIV sales up 18% (Biktarvy $4.06B, Descovy +49%, new launch Yeztugo at $305M) and Trodelvy up 42%, while Veklury collapsed 69% and Cell Therapy fell 18% on competitive headwinds. The nine-month bottom line swung to a $6.0 billion net loss (diluted EPS -$4.87) versus $6.3 billion net income a year ago, driven by roughly $11.3 billion of acquired IPR&D charges from the Arcellx ($6.4B), Tubulis ($3.2B) and Ouro Medicines ($1.9B) acquisitions plus a $1.75B IPR&D impairment — an aggressive pipeline rebuild paid for partly with $3.0B of new notes.
Key figures
- Eps
- 1.94
- Revenue
- 8300000000
- Net Income
- 2429000000
- Total Debt
- 26231000000
- Revenue Yoy
- 7%
- Total Assets
- 51408000000
- Cash Position
- 6437000000
- Shares Outstanding
- 1240338614
- Yeztugo q3
- 305000000
- Biktarvy q3
- 4059000000
- Descovy q3 yoy
- +49%
- Veklury q3 yoy
- -69%
- Trodelvy q3 yoy
- +42%
- Hiv sales q3 yoy
- +18%
- Q3 product sales
- 8289000000
- Q3 net income yoy
- -20%
- Buyback nine month
- 1144000000
- Nine month revenue
- 23063000000
- Arcellx acquisition
- 6400000000
- Cell therapy q3 yoy
- -18%
- Tubulis acquisition
- 3200000000
- Nine month revenue yoy
- 7%
- Product gross margin q3
- 81.0%
- Acquired iprnd nine month
- 11307000000
- Pepstar agreement upfront
- 1275000000
- Q3 diluted eps prior year
- 2.43
- Ouro medicines acquisition
- 1900000000
- Iprnd impairment nine month
- 1750000000
- Dividend per share quarterly
- 0.82
- Operating cash flow nine month
- 11152000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.